Mode
Text Size
Log in / Sign up
N/A Completed N=442

BRAVO: Background Regimen of Raltegravir on Virologic Outcome

Source: ClinicalTrials.gov NCT00751530 ↗
Enrolled (actual)
442
Serious AEs
—
Results posted
Jun 2011
Primary outcomePrimary: Percentage of Participants With Viral Load < 400 Copies /mL at Week 12. — 84; 86 Percentage of Participants

Summary

This is a retrospective chart review of participants in raltegravir expanded access program and will compare virologic response in regimens not containing a protease inhibitor in the antiretroviral background regimen to regimens containing a protease inhibitor in the background regimen.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Viral Load < 400 Copies /mL at Week 12.
84; 86 —
SECONDARY
Percentage of Participants With Viral Load < 75 Copies/ mL at Week 12
84; 86 —
SECONDARY
CD4 Cell Changes Among Participants in PI vs Non-PI Group
-96.6; -134.8 —
SECONDARY
Baseline Genotypic Sensitivity Score (GSS). The Minimal Value Was 0 and the Maximum Values Was 5.4. (0 = Minimal to no Activity in Regimen and 5.4 = High to Maximal Activity in Regimen)
1.8; 1.7 —
SECONDARY
Percentage of Participants Using Etravirine in Background Regimen
33; 58 —

Eligibility Criteria

Inclusion Criteria

  • Patients previously enrolled in the MK 0518 EAP are eligible
  • Patients not enrolled in the MK 0518 EAP (or other Raltegravir protocols) but who meet the specific EAP protocol entry criteria are eligible:
  • Age >= 16 years
  • Limited or no treatment options due to resistance or intolerance to multiple antiretroviral regimens, documented resistance to at least one drug in each of the 3 classes of oral ARTs (NRTI, NNRTI, PI) by genotype or phenotype testing, intolerance defined as having had a clinically significant adverse event which in the opinion of the clinician provides a contraindication to the use of any drug in that class iii. Patient did not achieve virologic suppression on ART regimen prior to receipt of raltegravir iv. Patient was clinically stable at time of initiation of raltegravir, eg. clinical status and all chronic medications (except ARTs) unchanged for >= 2 weeks prior to raltegravir receipt.
  • Patient received raltegravir for at least 8 weeks
  • Baseline and week 8 or later HIV viral load done and available for review
  • Resistance test (either genotypic or phenotypic test) available prior to receipt of raltegravir

Exclusion Criteria

  • Patient did not receive approved raltegravir dose of 400 mg BID for at least 8 weeks.
  • Patient chart not available for review.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00751530). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search